Literature DB >> 25205827

Belimumab after rituximab as maintenance therapy in lupus nephritis.

Tineke Kraaij1, Tom W J Huizinga1, Ton J Rabelink1, Y K Onno Teng2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25205827     DOI： 10.1093/rheumatology/keu369

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  13 in total

Review 1.  Inflammatory Joint Disorders and Neutrophilic Dermatoses: a Comprehensive Review.

Authors:  Massimo Cugno; Roberta Gualtierotti; Pier Luigi Meroni; Angelo Valerio Marzano
Journal:  Clin Rev Allergy Immunol       Date:  2018-04       Impact factor: 8.667

Review 2.  B Cell-Based Treatments in SLE: Past Experience and Current Directions.

Authors:  Stamatis-Nick C Liossis; Chrysanthi Staveri
Journal:  Curr Rheumatol Rep       Date:  2017-11-04       Impact factor: 4.592

Review 3.  New Trials in Lupus and where Are we Going.

Authors:  Aikaterini Thanou; Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2018-05-03       Impact factor: 4.592

4.  BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency.

Authors:  Paul J Maglione; Gavin Gyimesi; Montserrat Cols; Lin Radigan; Huaibin M Ko; Tamar Weinberger; Brian H Lee; Emilie K Grasset; Adeeb H Rahman; Andrea Cerutti; Charlotte Cunningham-Rundles
Journal:  JCI Insight       Date:  2019-03-07

Review 5.  Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.

Authors:  Domenico Paolo Emanuele Margiotta; Fabio Basta; Veronica Batani; Antonella Afeltra
Journal:  BMC Nephrol       Date:  2018-03-07       Impact factor: 2.388

6.  Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.

Authors:  Y K Onno Teng; Ian N Bruce; Betty Diamond; Richard A Furie; Ronald F van Vollenhoven; David Gordon; James Groark; Robert B Henderson; Mary Oldham; Paul P Tak
Journal:  BMJ Open       Date:  2019-03-20       Impact factor: 2.692

Review 7.  Individualizing Therapy in Lupus Nephritis.

Authors:  Yu An; Haitao Zhang; Zhihong Liu
Journal:  Kidney Int Rep       Date:  2019-08-20

8.  Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus.

Authors:  Marlene Plüß; Björn Tampe; Noah Niebusch; Michael Zeisberg; Gerhard A Müller; Peter Korsten
Journal:  Front Med (Lausanne)       Date:  2020-05-27

9.  Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study.

Authors:  David Jayne; Daniel Blockmans; Raashid Luqmani; Sergey Moiseev; Beulah Ji; Yulia Green; Leanne Hall; David Roth; Robert B Henderson; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2019-04-16       Impact factor: 10.995

10.  Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.

Authors:  Luca Petricca; Maria Rita Gigante; Annamaria Paglionico; Stefano Costanzi; Gisella Vischini; Clara Di Mario; Valentina Varriano; Giacomo Tanti; Barbara Tolusso; Stefano Alivernini; Giuseppe Grandaliano; Gianfranco Ferraccioli; Elisa Gremese
Journal:  Front Med (Lausanne)       Date:  2020-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.